A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies.

Norman MoullanJosephat AsiagoKathryn SteccoSalah HadiMoetaz AlbizemHolly TieuBjörn HockCraig FenwickKai LinThomas LengsfeldLauren PoffenbargerDavid LiuDidier TronoGiuseppe PantaleoRajeev VenkayyaPrakash K Bhuyan

Published in: Infectious diseases and therapy (2024)

EudraCT Number 2022-001709-35 (COV-2022-001).

Keyphrases

sars cov
respiratory syndrome coronavirus
endothelial cells
induced pluripotent stem cells
open label
pluripotent stem cells
phase ii
clinical trial
double blind
placebo controlled
study protocol